UAP1

UAP1 is the terminal enzyme of the hexosamine biosynthetic pathway, catalyzing the uridyltransfer reaction that produces UDP-N-acetylhexosamines from N-acetylhexosamine-1-phosphate and a nucleotide triphosphate, with the AGX1 isoform accepting UTP, dUTP, and dTTP to generate UDP-/dUDP-/dTDP-GalNAc in vitro (PMID:22595178). By supplying UDP-GlcNAc as the donor for N-linked glycosylation, UAP1 supports cellular proliferation and stress resistance: overexpression raises intracellular UDP-GlcNAc roughly ten-fold and confers resistance to N-linked glycosylation inhibitors, while knockdown re-sensitizes cells and triggers ER stress (PMID:25241896). Through this glycosylation-supporting activity UAP1 promotes the aggressive behavior of multiple cancers, where its loss reduces proliferation, migration, invasion, and N-linked glycosylation and shifts cell-cycle and EMT regulators (PMID:32650368, PMID:41452006). Beyond metabolism, UAP1 acts as a protein pyrophosphorylase that directly pyrophosphorylates IRF3 at Ser386 to drive robust type I interferon responses, with Uap1-deficient mice showing impaired antiviral IFN signaling and lethal susceptibility to DNA- and RNA-virus infection (PMID:36603579). A de novo p.A229T missense mutation that destabilizes the AGX1 isoform and alters its N-terminal domain conformation links UAP1 to an intellectual disability phenotype (PMID:33098688).

1. 1998 Medium

   Before any enzymatic role was assigned, the protein (as SPAG2) was placed at a discrete subcellular structure, establishing its presence as a novel non-intermediate-filament component of the sperm flagellar outer dense fibers.

   Evidence Immunofluorescence and electron microscopy of Triton-extracted spermatozoa, plus cDNA library screening

   PMID:9621304

   Open questions at the time

   • No functional consequence of ODF localization established
   • Relationship between this structural localization and the later-defined enzymatic activity unexplored
2. 2012 Medium

   The core biochemical activity was defined by reconstituting AGX1 as a uridyltransferase that synthesizes UDP-GalNAc and, unexpectedly, accepts deoxynucleotide substrates, mapping its substrate scope.

   Evidence In vitro enzymatic assay with systematic nucleotide substrate specificity profiling

   PMID:22595178

   Open questions at the time

   • In vitro substrate promiscuity (dUTP/dTTP) of unknown physiological relevance
   • No structural basis for substrate selection
   • Single lab, single method
3. 2014 Medium

   The metabolic output was linked to a cellular phenotype, showing that UAP1-driven UDP-GlcNAc supply sustains N-linked glycosylation and protects cancer cells from glycosylation-inhibitor-induced ER stress.

   Evidence siRNA/shRNA knockdown with proliferation and ER stress readouts, UDP-GlcNAc quantification, tissue microarray in prostate cancer cells

   PMID:25241896

   Open questions at the time

   • Specific glycoprotein clients not identified
   • Resistance shown only against glycosylation inhibitors, not general ER stress
4. 2020 High

   A disease-causing variant was characterized structurally and functionally, establishing that destabilization of the AGX1 isoform via a conformational shift in the N-terminal domain can produce a Mendelian neurodevelopmental phenotype.

   Evidence In vitro activity assay, X-ray crystallography, and site-directed mutagenesis of a patient-derived p.A229T variant

   PMID:33098688

   Open questions at the time

   • Causality at the organismal level not tested (no animal model of the variant)
   • Mechanistic connection between reduced enzymatic activity and intellectual disability not resolved
5. 2020 Medium

   The pro-tumorigenic role was extended beyond prostate to bladder cancer, generalizing UAP1 as a supporter of cancer-cell aggressiveness.

   Evidence siRNA knockdown with proliferation, invasion, colony formation, and migration assays in bladder cancer cell lines

   PMID:32650368

   Open questions at the time

   • Molecular mediators not defined in this system
   • No in vivo validation
6. 2023 High

   A non-canonical catalytic function was discovered: UAP1 acts as a protein pyrophosphorylase on IRF3 Ser386, revealing a direct enzymatic role in innate antiviral immunity distinct from its metabolic activity.

   Evidence Biochemical pyrophosphorylase assay, Uap1 knockout mice, viral infection models, IRF3 phosphorylation assays

   PMID:36603579

   Open questions at the time

   • How the same enzyme partitions between sugar-nucleotide synthesis and protein pyrophosphorylation is unresolved
   • Substrate scope of the pyrophosphorylase activity beyond IRF3 unknown
7. 2025 Medium

   Isoform-specific regulation was placed in a signaling axis, showing that NSUN2/SRSF6-controlled alternative splicing toward AGX2 enhances ABC-transporter glycosylation and stability to drive multidrug resistance.

   Evidence NSUN2 knockout cells, MeRIP-seq, proteomics, splicing analysis, glycoprotein staining, and denaturing ubiquitination IP in anaplastic thyroid cancer; CRISPR-Cas9 UAP1 knockout with lectin blots in lung cancer

   PMID:40083919 PMID:41452006

   Open questions at the time

   • Functional difference between AGX1 and AGX2 at the enzymatic level not fully defined
   • Direct interaction of AGX2 with ABC transporters not demonstrated
   • Single lab for the thyroid axis

• It remains unknown how UAP1 mechanistically toggles between its sugar-nucleotide pyrophosphorylase metabolic role, its IRF3 protein-pyrophosphorylase immune role, and its isoform-specific glycosylation-promoting role in disease.
• No structural or regulatory model linking the metabolic and protein-pyrophosphorylase activities
• Cellular determinants of AGX1 vs AGX2 functional specialization undefined